Elutia Inc.
$ 1.08
-6.09%
13 Mar - close price
- Market Cap 46,117,300 USD
- Current Price $ 1.08
- High / Low $ 1.19 / 1.06
- Stock P/E N/A
- Book Value 0.65
- EPS -0.93
- Next Earning Report 2026-05-07
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.23 %
- ROE N/A %
- 52 Week High 3.46
- 52 Week Low 0.50
About
Elutia Inc., a commercial-stage company, engages in developing and commercializing drug-eluting biomatrix technology to enhance surgical outcomes. The company is headquartered in Silver Spring, Maryland.
Analyst Target Price
$5.00
Quarterly Earnings
| Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-03-04 | 2025-11-06 | 2025-08-14 | 2025-05-07 | 2025-03-05 | 2024-11-14 | 2024-08-07 | 2024-05-09 | 2024-03-07 | 2023-11-13 | 2023-08-14 | 2023-05-10 |
| Reported EPS | 1.48 | -0.19 | -0.26 | -0.21 | -0.26 | 0.33 | -1.13 | -0.75 | -0.4 | -0.57 | -0.65 | -0.49 |
| Estimated EPS | -0.12 | -0.15 | -0.19 | -0.205 | -0.25 | -0.44 | -0.33 | -0.41 | -0.28 | -0.53 | -0.29 | -0.57 |
| Surprise | 1.6 | -0.04 | -0.07 | -0.005 | -0.01 | 0.77 | -0.8 | -0.34 | -0.12 | -0.04 | -0.36 | 0.08 |
| Surprise Percentage | 1333.3333% | -26.6667% | -36.8421% | -2.439% | -4% | 175% | -242.4242% | -82.9268% | -42.8571% | -7.5472% | -124.1379% | 14.0351% |
Next Quarterly Earnings
| Mar 2026 | |
|---|---|
| Reported Date | 2026-05-07 |
| Fiscal Date Ending | 2026-03-31 |
| Estimated EPS | -0.12 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: ELUT
2026-03-12 22:52:09
Elutia Inc.'s Chief Scientific Officer, Michelle LeRoux Williams, increased her direct stock ownership through the vesting of Restricted Stock Units. On March 10, 2026, 12,500 RSUs converted into Class A Common Stock, reflecting a previously granted equity award. This transaction is considered neutral in impact and sentiment according to Rhea-AI.
2026-03-10 22:51:30
Elutia (NASDAQ: ELUT) is set to announce its quarterly earnings on Wednesday, March 11, 2026, with analysts estimating an EPS of $-0.14. Investors are closely watching for potential news of the company surpassing estimates and providing positive guidance for the upcoming quarter. The company's past earnings performance shows a trend of missed EPS estimates, leading to negative stock price movements, and its shares have seen a significant decline of 63.18% over the last 52 weeks.
2026-03-09 21:52:53
Elutia Inc. adopted a 2026 Inducement Award Plan on March 3, 2026, authorizing 2,000,000 shares of Class A common stock for new hires to attract and retain talent without requiring shareholder approval. The plan grants the Compensation Committee broad authority over various equity awards and change-in-control treatments. Despite weak financial performance, the company aims to strengthen its workforce and align employee interests with shareholders through these equity incentives.
2026-03-09 20:52:14
This page provides the latest news and market updates for Elutia Inc. (ELUT), a regenerative medicine company focusing on drug-eluting biomatrix products. It covers recent developments such as compliance with Nasdaq listing requirements, executive appointments, financial results, and progress on their NXT-41 and NXT-41x biomatrix programs for reconstructive surgery. The company aims to leverage asset sale proceeds to fund the development and commercialization of these products.
2026-03-09 17:00:00
Elutia Inc. has adopted a 2026 Inducement Award Plan to provide equity-based incentives for newly hired employees, allowing for the grant of up to 2,000,000 shares of Class A common stock. This plan aims to attract and retain talent by offering various awards like stock options and restricted stock units, and does not require shareholder approval as it qualifies under Nasdaq Listing Rule 5635(c)(4). The Compensation Committee will administer the plan, setting terms and conditions for awards.
2026-03-04 20:52:14
Elutia Inc. announced that it has regained compliance with Nasdaq's minimum bid price and minimum market value of listed securities requirements. This means the company is now in full compliance with all Nasdaq continued listing requirements, and its Class A common stock will continue to trade under the symbol "ELUT." The CFO attributed the increased share price and market value to investor confidence in Elutia's drug-eluting biomatrix technology.
